Here, we compared primary tumor regrowth, survival, incidence of metastases and FDG uptake following PT and PTB adjuvant treatment in two resectable Her2 + breast cancer xenografts and have shown that BVZ combined with PAC and Trast (PTB) when delivered post resection provides no additional benefit compared with the PAC+ Trast(PT) combination. This evidence concerns the gene ERBB2 and breast carcinoma.